Stockscreener 앱 받기
77.52
2.54%
-2.02
시간 외 거래:
77.52
전일 마감가:
$79.54
열려 있는:
$79.41
하루 거래량:
279.06K
Relative Volume:
0.58
시가총액:
$5.17B
수익:
-
순이익/손실:
$-224.29M
주가수익비율:
-19.88
EPS:
-3.9
순현금흐름:
$-185.06M
1주 성능:
-4.25%
1개월 성능:
+4.69%
6개월 성능:
+3.39%
1년 성능:
-22.83%
1일 변동 폭
$76.95
$79.61
1주일 범위
$75.20
$82.81
52주 변동 폭
$55.53
$106.32
Nuvalent Inc Stock (NUVL) Company Profile
명칭
Nuvalent Inc
전화
508-446-2272
주소
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
NUVL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
77.52 | 5.74B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-03-14 | 업그레이드 | UBS | Neutral → Buy |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-10-24 | 개시 | UBS | Neutral |
| 2024-08-29 | 개시 | Barclays | Overweight |
| 2024-04-17 | 개시 | Jefferies | Buy |
| 2024-04-01 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 재개 | Guggenheim | Buy |
| 2024-02-23 | 개시 | Robert W. Baird | Outperform |
| 2023-09-27 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-24 | 개시 | Guggenheim | Buy |
| 2023-01-18 | 개시 | Wedbush | Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
모두보기
Nuvalent Inc 주식(NUVL)의 최신 뉴스
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day - The Malaysian Reserve
What to expect from Nuvalent Inc. in the next 30 daysTrade Ideas & Risk Controlled Swing Trade Alerts - newser.com
Cancer Drug Developer Nuvalent's CEO and CFO to Share Updates at UBS Virtual Oncology Conference - Stock Titan
5,700 Shares in Nuvalent, Inc. $NUVL Acquired by Strs Ohio - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of "Buy" from Analysts - MarketBeat
Intraday pattern recognizer results for Nuvalent Inc.Earnings Trend Report & Safe Capital Growth Trade Ideas - newser.com
Nuvalent completes FDA submission for lung cancer drug zidesamtinib - Investing.com India
Analyzing net buyer seller activity in Nuvalent Inc.July 2025 PostEarnings & Risk Managed Investment Entry Signals - newser.com
LifeSci Capital Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $110 - 富途牛牛
Nuvalent completes FDA submission for lung cancer drug zidesamtinib By Investing.com - Investing.com Nigeria
Nuvalent Completes New Drug Application Submission - TipRanks
Nuvalent (NASDAQ:NUVL) CEO Sells $2,135,160.00 in Stock - MarketBeat
Nuvalent, Inc. $NUVL Shares Bought by Voya Investment Management LLC - MarketBeat
Smart tools for monitoring Nuvalent Inc.’s price actionJuly 2025 Setups & Entry and Exit Point Strategies - newser.com
Market Review: Can Nuvalent Inc. beat the S&P 500Market Growth Summary & Pattern Based Trade Signal System - خودرو بانک
Can a trend reversal in Nuvalent Inc. lead to recovery2025 Growth vs Value & Daily Momentum Trading Reports - newser.com
Is Nuvalent Inc. reversing from oversold territoryJuly 2025 Weekly Recap & Fast Entry High Yield Stock Tips - newser.com
Aug Patterns: Does Nuvalent Inc have a sustainable dividendShare Buyback & Low Drawdown Investment Strategies - خودرو بانک
Aug Final Week: Does Nuvalent Inc stock benefit from AI growthJuly 2025 Spike Watch & Target Return Focused Picks - خودرو بانک
Is this a good reentry point in Nuvalent Inc.Portfolio Risk Summary & Risk Adjusted Swing Trade Ideas - newser.com
What momentum shifts mean for Nuvalent Inc.July 2025 Breakouts & Smart Money Movement Tracker - newser.com
Risk adjusted return profile for Nuvalent Inc. analyzedDollar Strength & Real-Time Buy Signal Alerts - newser.com
Does Nuvalent’s Recent FDA Breakthrough Designation Signal a New Opportunity for Investors in 2025? - Yahoo Finance
Chart overlay techniques for tracking Nuvalent Inc.Weekly Profit Summary & Risk Managed Investment Entry Signals - newser.com
Henry E. Pelish Sells 3,725 Shares of Nuvalent (NASDAQ:NUVL) Stock - MarketBeat
Voya Investment Management LLC Has $8.53 Million Holdings in Nuvalent, Inc. $NUVL - Defense World
Sector ETF performance correlation with Nuvalent Inc.Market Trend Review & Smart Allocation Stock Reports - newser.com
Nuvalent (NUVL): Assessing Valuation Following Subtle Shifts in Investor Sentiment - Yahoo Finance
Surprises Report: Should I buy Nuvalent Inc stock nowMarket Sentiment Summary & Stepwise Trade Signal Implementation - خودرو بانک
Aug Selloffs: Is Nuvalent Inc stock a value trap2025 Pullback Review & Consistent Income Trade Recommendations - خودرو بانک
Aug Levels: Is Nuvalent Inc stock a value trapWeekly Stock Analysis & Risk Controlled Stock Alerts - خودرو بانک
Dividend Watch: Should I set a stop loss on Nuvalent IncJuly 2025 Levels & AI Forecast Swing Trade Picks - خودرو بانک
Stock Analysis: Should I buy Nuvalent Inc stock now2025 Market Sentiment & Free Verified High Yield Trade Plans - خودرو بانک
Tech Rally: Can RFAI grow without external fundingJuly 2025 Sentiment & High Conviction Investment Ideas - خودرو بانک
Nuvalent Inc (NUVL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nuvalent Inc 주식 (NUVL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Porter James Richard | President and CEO |
Sep 15 '25 |
Sale |
79.08 |
27,000 |
2,135,055 |
249,062 |
| Pelish Henry E. | Chief Scientific Officer |
Sep 10 '25 |
Option Exercise |
26.94 |
3,725 |
100,354 |
69,688 |
| Pelish Henry E. | Chief Scientific Officer |
Sep 10 '25 |
Sale |
78.83 |
3,725 |
293,642 |
65,963 |
2.43%
자본화:
|
볼륨(24시간):